# ABK Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abk-biomedical

- Industry: Medical Devices & Equipment
- Headquarters: Halifax, Canada
- Website: www.abkbiomedical.com
- Total disclosed funding: $102M
- Latest round: Series D (Oct 14, 2025)
- Investors on record: 6

## About

ABK Biomedical Inc. is a Canadian company specializing in innovative medical devices that enhance treatment outcomes for patients with liver tumors through advanced technologies in radioembolization. Founded in 2012 in Halifax, Canada, ABK Biomedical Inc. focuses on developing solutions for liver tumor treatment. In October 2025, ABK Biomedical Inc. raised USD 35 million in series D funding led by JP Morgan Life Sciences Private Capital, including F-Prime Capital, Sante Ventures, and Eight Roads Ventures. ABK Biomedical, Inc. specializes in developing and commercializing advanced medical devices for liver tumor treatments. Its key product, Eye90 microspheres®, utilizes a unique glass composition for visualizing Yttrium-90 (Y90) procedures, enhancing precision in treating hepatocellular carcinoma and other liver malignancies. The company also provides Easi-Vue™ embolic microspheres for embolizing arteriovenous malformations and hypervascular tumors, primarily catering to healthcare providers in North America and expanding in Europe and Asia.ABK Biomedical operates through direct sales to healthcare institutions and professionals, generating revenue from innovative products like Eye90 microspheres® and Easi-Vue™ embolic microspheres. These products are typically procured by hospitals for clinical use, with ongoing partnerships in interventional oncology facilitating their adoption, supported by recent FDA approvals that improve market access.In December 2022, ABK Biomedical Inc. raised USD 30.00 mn in Series C funding to advance the development of its Easi-Vue™ embolic microspheres technology. The company will use the October 2025 funding to support clinical trials, prepare for Eye90 microspheres commercialization, and expand manufacturing and supply chain operations.

## Funding rounds

- Series D, Oct 14, 2025, $35M — Eight Roads Ventures, F-Prime Capital, Sante Ventures, JP Morgan Life Sciences Private Capital
- Series C, Dec 6, 2022, $30M — Eight Roads Ventures, F-Prime Capital, Sante Ventures
- Series B, Apr 8, 2019, $30M — F-Prime Capital, Varian Medical Systems, Inc.
- Series A, Jun 22, 2016, $7.2M — Invest Nova Scotia
- Seed, Sep 15, 2012 — Invest Nova Scotia

## Investors

- Invest Nova Scotia — Seed, Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B, Series C, Series D
- Varian Medical Systems, Inc. — Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series C, Series D
- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series C, Series D
- JP Morgan Life Sciences Private Capital (https://capitalatlas.ai/funds/jp-morgan-life-sciences-private-capital) — Series D